Nordic Gold (CVE:NOR) Stock Price Up 20%

Share on StockTwits

Nordic Gold Inc (CVE:NOR) shares rose 20% on Tuesday . The stock traded as high as C$0.03 and last traded at C$0.03, approximately 300,830 shares traded hands during mid-day trading. An increase of 114% from the average daily volume of 140,484 shares. The stock had previously closed at C$0.03.

The company’s fifty day moving average price is C$0.04 and its two-hundred day moving average price is C$0.04. The company has a current ratio of 0.07, a quick ratio of 0.03 and a debt-to-equity ratio of 59.42. The firm has a market cap of $4.89 million and a P/E ratio of -0.17.

Nordic Gold Company Profile (CVE:NOR)

Nordic Gold Corp., a junior mining company, engages in the acquisition and exploration of gold, precious, and base metal properties primarily in Canada and internationally. It holds 100% interest in the Laiva Mine property located in Raahe, Finland; and 49% interest in the Sheslay that comprise 19 mineral claim licenses located in the Atlin mining division of northwestern British Columbia, Canada.

Read More: Current Ratio

Receive News & Ratings for Nordic Gold Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nordic Gold and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Trigon Metals  Receives Daily Media Sentiment Score of 0.57
Trigon Metals Receives Daily Media Sentiment Score of 0.57
Head-To-Head Contrast: Orexigen Therapeutics  & Novus Therapeutics
Head-To-Head Contrast: Orexigen Therapeutics & Novus Therapeutics
Perdoceo Education  and Its Peers Head to Head Comparison
Perdoceo Education and Its Peers Head to Head Comparison
Auxly Cannabis Group  and PRA Health Sciences  Financial Contrast
Auxly Cannabis Group and PRA Health Sciences Financial Contrast
Analyzing Teva Pharmaceutical Industries  & Amicus Therapeutics
Analyzing Teva Pharmaceutical Industries & Amicus Therapeutics
Comparing Sangamo Therapeutics  & Biogen
Comparing Sangamo Therapeutics & Biogen


© 2006-2020 Ticker Report